Logo image of ELAN

ELANCO ANIMAL HEALTH INC (ELAN) Stock Price, Forecast & Analysis

USA - NYSE:ELAN - US28414H1032 - Common Stock

21.31 USD
-0.15 (-0.7%)
Last: 11/20/2025, 2:35:59 PM

ELAN Key Statistics, Chart & Performance

Key Statistics
Market Cap10.59B
Revenue(TTM)4.59B
Net Income(TTM)36.00M
Shares496.81M
Float491.31M
52 Week High23.09
52 Week Low8.02
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)0.96
PE22.2
Fwd PE20.82
Earnings (Next)02-23 2026-02-23/amc
IPO2018-09-20
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


ELAN short term performance overview.The bars show the price performance of ELAN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60

ELAN long term performance overview.The bars show the price performance of ELAN in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60 80

The current stock price of ELAN is 21.31 USD. In the past month the price decreased by -0.83%. In the past year, price increased by 60.63%.

ELANCO ANIMAL HEALTH INC / ELAN Daily stock chart

ELAN Latest News, Press Relases and Analysis

ELAN Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 47.64 991.60B
JNJ JOHNSON & JOHNSON 19.59 489.78B
MRK MERCK & CO. INC. 10.78 237.31B
PFE PFIZER INC 7.64 138.92B
BMY BRISTOL-MYERS SQUIBB CO 6.99 93.32B
ZTS ZOETIS INC 18.35 51.56B
RPRX ROYALTY PHARMA PLC- CL A 9.28 22.25B
VTRS VIATRIS INC 4.39 11.93B
CORT CORCEPT THERAPEUTICS INC 86.32 8.00B
AXSM AXSOME THERAPEUTICS INC N/A 7.17B
BLTE BELITE BIO INC - ADR N/A 3.89B
CRNX CRINETICS PHARMACEUTICALS IN N/A 4.08B

About ELAN

Company Profile

ELAN logo image Elanco Animal Health, Inc. develops, manufactures, and markets products for pets and farm animals. The company is headquartered in Greenfield, Indiana and currently employs 9,000 full-time employees. The company went IPO on 2018-09-20. The firm's product portfolio is sold in more than 90 countries and serves animals across many species, primarily dogs and cats (collectively, pet health) and cattle, poultry, swine, and sheep (collectively, farm animal). The company has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. The firm's global pet health portfolio is focused on parasiticides, vaccines and therapeutics. Its pet health products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its farm animal products include AviPro, Baytril, Catosal, Denagard, Experior, Hemicell, Maxiban/Monteban, Pulmotil, Rumensin, and Surmax. Its customers include consultants, veterinarians, farm animal producers and resellers.

Company Info

ELANCO ANIMAL HEALTH INC

2500 Innovation Way N

Greenfield INDIANA 46140 US

CEO: Jeffrey N. Simmons

Employees: 9000

ELAN Company Website

ELAN Investor Relations

Phone: 18773526261

ELANCO ANIMAL HEALTH INC / ELAN FAQ

What does ELANCO ANIMAL HEALTH INC do?

Elanco Animal Health, Inc. develops, manufactures, and markets products for pets and farm animals. The company is headquartered in Greenfield, Indiana and currently employs 9,000 full-time employees. The company went IPO on 2018-09-20. The firm's product portfolio is sold in more than 90 countries and serves animals across many species, primarily dogs and cats (collectively, pet health) and cattle, poultry, swine, and sheep (collectively, farm animal). The company has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. The firm's global pet health portfolio is focused on parasiticides, vaccines and therapeutics. Its pet health products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its farm animal products include AviPro, Baytril, Catosal, Denagard, Experior, Hemicell, Maxiban/Monteban, Pulmotil, Rumensin, and Surmax. Its customers include consultants, veterinarians, farm animal producers and resellers.


What is the current price of ELAN stock?

The current stock price of ELAN is 21.31 USD. The price decreased by -0.7% in the last trading session.


Does ELAN stock pay dividends?

ELAN does not pay a dividend.


What is the ChartMill rating of ELANCO ANIMAL HEALTH INC stock?

ELAN has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


What do analysts say about ELANCO ANIMAL HEALTH INC (ELAN) stock?

21 analysts have analysed ELAN and the average price target is 22.35 USD. This implies a price increase of 4.87% is expected in the next year compared to the current price of 21.31.


What is the employee count for ELAN stock?

ELANCO ANIMAL HEALTH INC (ELAN) currently has 9000 employees.


Can you provide the short interest for ELAN stock?

The outstanding short interest for ELANCO ANIMAL HEALTH INC (ELAN) is 4.49% of its float.


ELAN Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to ELAN. When comparing the yearly performance of all stocks, ELAN is one of the better performing stocks in the market, outperforming 92.51% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ELAN Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to ELAN. ELAN has only an average score on both its financial health and profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ELAN Financial Highlights

Over the last trailing twelve months ELAN reported a non-GAAP Earnings per Share(EPS) of 0.96. The EPS increased by 12.94% compared to the year before.


Industry RankSector Rank
PM (TTM) 0.78%
ROA 0.27%
ROE 0.53%
Debt/Equity 0.59
Chartmill High Growth Momentum
EPS Q2Q%46.15%
Sales Q2Q%10.39%
EPS 1Y (TTM)12.94%
Revenue 1Y (TTM)3.08%

ELAN Forecast & Estimates

21 analysts have analysed ELAN and the average price target is 22.35 USD. This implies a price increase of 4.87% is expected in the next year compared to the current price of 21.31.

For the next year, analysts expect an EPS growth of 1.26% and a revenue growth 4.03% for ELAN


Analysts
Analysts81.9
Price Target22.35 (4.88%)
EPS Next Y1.26%
Revenue Next Year4.03%

ELAN Ownership

Ownership
Inst Owners109.76%
Ins Owners0.95%
Short Float %4.49%
Short Ratio4.02